Research programme: Dravet syndrome therapeutics - Xenon

Drug Profile

Research programme: Dravet syndrome therapeutics - Xenon

Alternative Names: XEN-901

Latest Information Update: 10 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dravet syndrome

Most Recent Events

  • 04 Dec 2017 Xenon Pharmaceuticals plans a phase II trial for Epilepsy in late 2018
  • 17 Oct 2017 Xenon Pharmaceuticals files an IND equivalent application in Canada for Epilepsy
  • 09 Jan 2017 Xenon Pharmaceuticals announces intention to submit an IND application for the treatment of Dravet syndrome in the fourth quarter 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top